Why Immunotherapy Costs Less at KCC Than You Think

Picture a patient we see often at our City Clinic , a man in his late fifties from Kathmandu , years of khaini behind him, head and neck cancer that came back after his first round of chemotherapy. His son had already looked up immunotherapy online and found what everyone finds: it works, and it costs more than the family could raise. That used to be where the conversation ended. At KCC it doesn't anymore, and the reason isn't a discount, it's a flexible dose.

How does immunotherapy actually work?

Nivolumab, the drug his oncologist would actually prescribe, doesn't kill cancer cells directly. Cancer protects itself by growing a protein called PD-L1, which switches off the T-cells that would otherwise attack it. Nivolumab blocks that protein so the T-cells can recognise the cancer again, and the immune system does the rest of the work. That's also why he'd likely keep his hair and skip the worst of the nausea chemo gave him: the drug isn't poisoning his cells, it's unmasking them to his own body. (See our full guide to how immunotherapy works for the checkpoint inhibitors we use most, nivolumab and pembrolizumab.)

Why is immunotherapy so expensive everywhere else?

What his son found online was the price for the full dose, the one calibrated for a US or European market. What he wouldn't have found easily is that doctors at Tata Memorial Hospital in Mumbai had already asked whether that full dose was actually necessary. A single vial cost more than most families in the region earned in months. The drug wasn't the problem. The price was . Because in their own hospital only about 3 in 100 patients who could benefit from immunotherapy could afford it.

What does the research actually show?

The first answer came in 2023, in a trial led done there and published in the Journal of Clinical Oncology. Patients with advanced head and neck cancer, a disease painfully common in Nepal because of tobacco and betel nut use, were given a small dose of nivolumab alongside cheap oral chemotherapy tablets and it extended survival. A larger research a few years later, called DELII, this time in 500 patients across several cancer types giving 500 patients a twelfth (1/12) of the standard dose against standard chemotherapy, found patients lived longer, had fewer serious side effects, and were more likely to be alive a year on. It's a modest gain, not a cure, and that trial never tested low-dose against full-dose directly, so nobody can say the two perform identically. What it showed is that the low dose clearly beats the chemotherapy only, most patients were actually being offered, at a small fraction of the price our patient's son had found online.

A follow-up study went further for head and neck cancer specifically, and this is the regimen closest to what our man in Kathmandu would likely get: the same low dose of nivolumab paired with three inexpensive oral chemotherapy drugs, instead of standard injection chemotherapy . In that study, this combination cut the risk of death by nearly half , nearly doubled how many patients responded, and caused fewer serious side effects, with survival stretching from around six months to just over ten.

Why has KCC offered this since 2022?

We didn't wait for these papers to change what we do. KCC has given flexible, low-dose immunotherapy since 2022, on the strength of the earlier research from Belgium, because charging full international pricing here never made sense in country like Nepal For our patient, that means the conversation with his son doesn't end at the price anymore.

How much does immunotherapy cost at KCC?

| Protocol | Dose | Approx. cost per cycle |``|---|---|---|``| KCC flexible/low-dose (DELII protocol) | 20 mg | ~NPR 12,000–15,000 |``| Standard/full dose, priced locally | 240 mg | ~NPR 1,40,000–1,60,000 |``| Standard/full dose, USA list price | 240 mg | ~$8,100 (~NPR 12,40,000) |

At KCC, a cycle of low-dose immunotherapy (20mg, the dose used in the DELII trial) typically costs somewhere around NPR 10,000–15,000. The same drug at the internationally approved standard dose, 240mg, the flat dose used in the US and Europe, would run roughly NPR 1,40,000–1,60,000 per cycle at that same rate. In the United States itself, a single 240mg dose of Opdivo (nivolumab) carries a list price of about $8,100, or roughly NPR 12,40,000, before insurance.

That makes our flexible-dose protocol roughly 90% cheaper than a full standard dose priced at the same local rate, and close to 99% cheaper than what the same drug costs in the US. These are drug-cost estimates per cycle only; exact pricing depends on the patient's dose and cancer type, and doesn't include consultation, infusion, or lab charges. You can request a written, case-specific estimate before deciding anything , please see the bottom of this page.

Will immunotherapy work for my cancer?

It also doesn't start with a guarantee. Whether immunotherapy will work for a given cancer depends on tests run on the biopsy tissue, checking things like PD-L1 levels or how the tumour's genes behave, and we can usually run these on a sample he already has rather than taking a new biopsy. Our tumour board at KCC looks at the cancer type, its stage, and his overall health before settling on a dose. The flexibility isn't a blanket discount; it's a decision this research lets us make responsibly. (Read more on biomarker testing at KCC and our head and neck cancer treatment page.)

What about patients already started treatment India?

If he'd already started treatment , none of that would need to restart. A treatment summary and recent reports sent over WhatsApp or Email are usually enough for us to confirm drug availability and continue an existing cycle schedule within a few days — see our transferring treatment from India guide .

Where can I actually get treated, and how far do I have to travel each cycle?

There's one more thing that would matter to his son, who has a shop to run and can't take a half-day off every two weeks: the infusion itself only takes thirty to sixty minutes, but getting to Bhaktapur, Tathali and back used to be the real cost. That's why we opened a City Clinic in New Baneshwor, in the middle of Kathmandu, so a trip to Bhaktapur isn't needed.

For a written estimate specific to your case, send the diagnosis, biopsy report, and any biomarker results you already have to KCC on WhatsApp at 9818-226237. You'll usually hear back within 24 hours, before you need to decide anything.

This article was reviewed by Dr. Subhas Pandit, Clinical Oncologist and Academic & Research Director at Kathmandu Cancer Center. It is intended for general information and does not replace individual medical advice. For a diagnosis-specific opinion, contact KCC directly.